Jain, Raksha

Elexacaftor–Tezacaftor–Ivacaftor for Cystic Fibrosis with a Single Phe508del Allele

Middleton, P. G., Mall, M. A., Dřevínek, P., Lands, L. C., McKone, E. F., Polineni, D., Ramsey, B. W., Taylor-Cousar, J. L., Tullis, E., Vermeulen, F., et al. (2019) · New England Journal of Medicine

Cystic Fibrosis Research AdvancesInhalation and Respiratory Drug Delivery

Cited by 2,198

Efficacy and safety of the elexacaftor plus tezacaftor plus ivacaftor combination regimen in people with cystic fibrosis homozygous for the F508del mutation: a double-blind, randomised, phase 3 trial

Heijerman, H. G. M., McKone, E. F., Downey, D. G., Van Braeckel, E., Rowe, S. M., Tullis, E., Mall, M. A., Welter, J. J., Ramsey, B. W., McKee, C. M., et al. (2019) · The Lancet

Cystic Fibrosis Research AdvancesPharmacogenetics and Drug Metabolism

Cited by 1,414

Long-term safety and efficacy of tezacaftor-ivacaftor in individuals with cystic fibrosis aged 12 years or older who are homozygous or heterozygous for Phe508del CFTR (EXTEND): an open-label extension study

Flume, P. A., Biner, R. F., Downey, D. G., Brown, C., Jain, M., Fischer, R., De Boeck, K., Sawicki, G. S., Chang, P., Paz-Diaz, H., et al. (2021) · The Lancet Respiratory Medicine

Cystic Fibrosis Research AdvancesInhalation and Respiratory Drug Delivery

Cited by 52